| http://purl.uniprot.org/citations/25131316 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/25131316 | http://www.w3.org/2000/01/rdf-schema#comment | "No disease-modifying therapies are available for synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple systems atrophy (MSA). The lack of therapies has been impeded by a paucity of validated drug targets and problematic cell-based model systems. New approaches are therefore needed to identify genes and compounds that directly target the underlying cellular pathologies elicited by the pathological protein, α-synuclein (α-syn). This small, lipid-binding protein impinges on evolutionarily conserved processes such as vesicle trafficking and mitochondrial function. For decades, the genetically tractable, single-cell eukaryote, budding yeast, has been used to study nearly all aspects of cell biology. More recently, yeast has revealed key insights into the underlying cellular pathologies caused by α-syn. The robust cellular toxicity caused by α-syn expression facilitates unbiased high-throughput small-molecule screening. Critically, one must validate the discoveries made in yeast in disease-relevant neuronal models. Here, we describe two recent reports that together establish yeast-to-human discovery platforms for synucleinopathies. In this exemplar, genes and small molecules identified in yeast were validated in patient-derived neurons that present the same cellular phenotypes initially discovered in yeast. On validation, we returned to yeast, where unparalleled genetic approaches facilitated the elucidation of a small molecule's mode of action. This approach enabled the identification and neuronal validation of a previously unknown "druggable" node that interfaces with the underlying, precipitating pathologies caused by α-syn. Such platforms can provide sorely needed leads and fresh ideas for disease-modifying therapy for these devastating diseases."xsd:string |
| http://purl.uniprot.org/citations/25131316 | http://purl.org/dc/terms/identifier | "doi:10.1002/mds.25989"xsd:string |
| http://purl.uniprot.org/citations/25131316 | http://purl.uniprot.org/core/author | "Chung C.Y."xsd:string |
| http://purl.uniprot.org/citations/25131316 | http://purl.uniprot.org/core/author | "Lindquist S."xsd:string |
| http://purl.uniprot.org/citations/25131316 | http://purl.uniprot.org/core/author | "Tardiff D.F."xsd:string |
| http://purl.uniprot.org/citations/25131316 | http://purl.uniprot.org/core/author | "Khurana V."xsd:string |
| http://purl.uniprot.org/citations/25131316 | http://purl.uniprot.org/core/date | "2014"xsd:gYear |
| http://purl.uniprot.org/citations/25131316 | http://purl.uniprot.org/core/name | "Mov Disord"xsd:string |
| http://purl.uniprot.org/citations/25131316 | http://purl.uniprot.org/core/pages | "1231-1240"xsd:string |
| http://purl.uniprot.org/citations/25131316 | http://purl.uniprot.org/core/title | "From yeast to patient neurons and back again: powerful new discovery platform."xsd:string |
| http://purl.uniprot.org/citations/25131316 | http://purl.uniprot.org/core/volume | "29"xsd:string |
| http://purl.uniprot.org/citations/25131316 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/25131316 |
| http://purl.uniprot.org/citations/25131316 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/25131316 |
| http://purl.uniprot.org/uniprot/#_P34110-mappedCitation-25131316 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/25131316 |
| http://purl.uniprot.org/uniprot/#_P39940-mappedCitation-25131316 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/25131316 |
| http://purl.uniprot.org/uniprot/#_Q08109-mappedCitation-25131316 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/25131316 |
| http://purl.uniprot.org/uniprot/#_P32805-mappedCitation-25131316 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/25131316 |
| http://purl.uniprot.org/uniprot/P32805 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/25131316 |
| http://purl.uniprot.org/uniprot/P34110 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/25131316 |
| http://purl.uniprot.org/uniprot/Q08109 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/25131316 |
| http://purl.uniprot.org/uniprot/P39940 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/25131316 |